The latest biotech news

sloth crossing the road Scenic Shutterbug fi

News and Trends 2 Dec 2016

Stories We Didn’t Cover: MDMA in Phase III, Another Death for Carmat

Try as we might, we can’t cover all the biotech news out there. During the week, we only pick the top stories to keep you informed but not waste your time. Here’s a roundup of news that didn’t make the cut this week. Sanofi has acquired Warp Drive Bio’s antibiotics program, which was born out of […]

December 2, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 2 Dec 2016

Better than ADCs? AstraZeneca bids for Bicyclic Peptides

AstraZeneca has signed a deal with Bicycle Therapeutics that could exceed €1B. The foundation is bicyclic peptides, which combine the best of antibodies and small molecules. Could Bicycle Drug Conjugates (BDCs) outperform ADCs? Bicycle Therapeutics is a company in Cambridge founded by one of the top biotech leaders in the UK’s golden triangle. Its unique technology […]

December 2, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Screenshot 2016 12 01 at 3.06.48 PM e1480601295300

News and Trends 2 Dec 2016

Mind, Mood and Microbes: Harnessing the Power of Probiotics

The canals of Amsterdam have attracted us this week to the capital of the Netherlands, where Winclove Probiotics has been working for more than 20 years in targeting the human microbiome. This field is now resurging, with research pointing to a close link between gut bacteria and human health. City: Amsterdam, the Netherlands Founded: 1991 Employees: 50+ Financial […]

December 2, 2016 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 1 Dec 2016

Evotec gets hold of CRISPR in a new Partnership with Merck

Evotec teamed up with Merck to boost its drug discovery services with CRISPR, entering the battlefield for the patent behind the discovery of the century. Apart from being a pioneer in the translation of research from academia to the clinic, Evotec is a successful CRO with top-level partners including Bayer, Roche, Sanofi, Boehringer Ingelheim and Takeda. The German company is […]

December 1, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 1 Dec 2016

Spain joins the Antibody-Drug Conjugate Bandwagon to fight Cancer

PharmaMar announced positive preclinical results for an ADC candidate, showing that the traditional chemistry-based pharma companies are shifting towards the new generation of biologicals. PharmaMar is an oncology pharma in Madrid mining a vast source for drug discovery: marine organisms. The company is now pivoting to a more innovative technology with the announcement of positive […]

December 1, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 1 Dec 2016

7 European Institutions in the Largest Cancer Bioinformatics Collaboration

Europe’s best companies using bioinformatics to tackle cancer will take part in a huge collaboration aimed at developing personalized cancer vaccines. Three biotech companies and four research institutions from Europe are taking part in the Tumor Neoantigen Selection Alliance (TESLA). This is one of the biggest oncology collaborations ever, consisting of 30 organizations and led by […]

December 1, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 1 Dec 2016

UPDATE: The HIV Frontier starts Phase III Vaccine trials in South Africa

Update (01/12/2016): The HVTN 702 trial has been started, making it the first HIV vaccine efficacy study in 7 years worldwide. Results are expected in late 2020. Originally published 25/07/2016 A Phase IIb/III trial for an experimental HIV vaccine just started in South Africa. The therapy, co-funded by the NIH and the Gates Foundation, is a combination […]

December 1, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 1 Dec 2016

It’s World AIDS Day, is Biotech close to an HIV Cure?

Biotech is working hard on developing an HIV cure, as well as fast diagnostics and vaccines. For those living with the disease, 2016 seems to be bringing new hope from the hands of science. Today, the 1st of December, is World AIDS Day. More than 36 million people live with HIV and 1 million died last year. The […]

December 1, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 30 Nov 2016

FDA and EMA review the First Therapy for a Deadly Skin Cancer

Merck and Pfizer have been granted priority review by the FDA for the first treatment dealing with one of the most aggressive forms of skin cancer. The FDA has accepted Merck and Pfizer‘s market application for avelumab in metastatic Merkel cell carcinoma (MCC) with priority review. Just a month ago, the EMA also accepted their application. If […]

November 30, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 30 Nov 2016

UPDATE: GSK is staging a comeback with a new Shingles Vaccine

GSK is banishing concerns about its health with a BLA submission for Shingrix, which has outperformed Merck’s standard and could bring GSK close to €1Bn. London-based GSK has just submitted a Biologics License Application to the FDA for its shingles vaccine candidate, Shingrix. Though it is still experimental, the vaccine is proving itself superior to the […]

November 30, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 30 Nov 2016

Drugging the Undruggable: New Acquisition to Boost GPCR Drugs

Heptares Therapeutics has acquired G7 Therapeutics to take control over its GPCR technology, boost its pipeline and keep competitors in this profitable field at bay. Heptares Therapeutics develops therapies directed to G protein-coupled receptors (GPCRs), a large family of hot but elusive targets for biopharma. The British company, owned by the Japanese Sosei, just announced it […]

November 30, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 30 Nov 2016

This was Labiotech Refresh! Check our recap and highlight video!

Six months have passed since the last time we opened the doors for the very first Labiotech Refresh, Europe’s most refreshing Biotech Conference. Last week we launched our second edition live from Le Machine du Moulin Rouge in Paris! Were you not able to attend? Don’t worry! Here is our highlight video: And here’s also a […]

November 30, 2016 - 5 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Stories We Didn’t Cover: MDMA in Phase III, Another Death for Carmat

Better than ADCs? AstraZeneca bids for Bicyclic Peptides

Mind, Mood and Microbes: Harnessing the Power of Probiotics

Evotec gets hold of CRISPR in a new Partnership with Merck

Spain joins the Antibody-Drug Conjugate Bandwagon to fight Cancer

7 European Institutions in the Largest Cancer Bioinformatics Collaboration

UPDATE: The HIV Frontier starts Phase III Vaccine trials in South Africa

It’s World AIDS Day, is Biotech close to an HIV Cure?

FDA and EMA review the First Therapy for a Deadly Skin Cancer

UPDATE: GSK is staging a comeback with a new Shingles Vaccine

Drugging the Undruggable: New Acquisition to Boost GPCR Drugs

This was Labiotech Refresh! Check our recap and highlight video!

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!